Form 4: Director O'Brien Acquires Eastman Chemical Phantom Stock Units

Director James J. O'Brien acquired 487 phantom stock units of Eastman Chemical through a deferral of director's fees.

Summary

• Director James J. O'Brien acquired 487 phantom stock units of Eastman Chemical Co. on October 7, 2025, at a price of $0.
• The acquisition was due to the automatic deferral of a portion of the director's annual retainer fees into the Directors' Deferred Compensation Plan.
• Following the transaction, O'Brien directly owns 17,407 derivative securities, which includes 395 units credited since April 7, 2025, as hypothetical reinvestment of dividend equivalents.

Sentiment

Score: 5

Explanation: The filing represents a routine transaction related to director compensation. It is neither overwhelmingly positive nor negative.

Positives

• Director O'Brien's increased holdings in Eastman Chemical Co. may reflect confidence in the company's future performance.
• The deferral of director's fees into phantom stock units aligns the director's interests with those of the shareholders.

Future Outlook

The phantom stock units are payable only in cash after termination of service as a director, indicating a long-term alignment with the company's performance.

Management Comments

• Automatic deferral of a portion of director's annual retainer fees into the director's stock account of the Directors' Deferred Compensation Plan, which would otherwise have been paid in cash.

Industry Context

This filing is a routine disclosure of insider transactions, which are common for directors of publicly traded companies. It reflects standard practices for aligning director compensation with company performance.

Comparison to Industry Standards

• Director deferred compensation plans are a common practice among publicly traded companies to align the interests of directors with those of shareholders.
• Many companies in the chemical industry, such as Dow and BASF, offer similar deferred compensation plans to their directors.
• The amount of deferred compensation and the structure of phantom stock units are generally comparable to industry standards.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders by aligning director compensation with company performance.

Key Dates

Recommendation

The transaction is a routine part of director compensation and does not provide a basis for changing a hold recommendation.

Keywords

Eastman Chemical, Director, Phantom Stock Units, Deferred Compensation, SEC Form 4, Insider Trading